Featured
-
-
Article |
Factors associated with the melanoma diagnostic interval in Ontario, Canada: a population-based study
- Meaghan E. Mavor
- , Timothy P. Hanna
- & Patti A. Groome
-
Article |
Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases
- Pascale Mariani
- , Nouritza Torossian
- & Raymond Barnhill
-
Article
| Open AccessUse of methotrexate and risk of skin cancer: a nationwide case–control study
- Sam Polesie
- , Martin Gillstedt
- & Kasper Kristensen
-
Correspondence |
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
- Monique K. van der Kooij
- , Arjen Joosse
- & Ellen Kapiteijn
-
Article |
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations
- Seungyeon Jung
- , Emma Armstrong
- & Douglas B. Johnson
-
Article |
Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors
- Yuting Li
- , Qinghua Wang
- & Lujun Zhao
-
Article |
M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors
- C. Barceló
- , P. Sisó
- & A. Macià
-
Article
| Open AccessCirculating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma
- Victoria G. Woof
- , Rebecca J. Lee
- & David P. French
-
Article
| Open AccessQuantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
- Sara J. Hamis
- , Yury Kapelyukh
- & Mark A. J. Chaplain
-
Article |
Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma
- Sarah Bouchereau
- , Louise Chaplain
- & Elisa Funck-Brentano
-
Article
| Open AccessAssociation between physical activity, grip strength and sedentary behaviour with incidence of malignant melanoma: results from the UK Biobank
- Andrea Weber
- , Michael F. Leitzmann
- & Sebastian E. Baumeister
-
Comment
| Open AccessSunglasses to hide behind may also prevent melanoma of the eyes
- Nathalie Dhomen
- , Piyushkumar A. Mundra
- & Richard Marais
-
Article
| Open AccessCheckpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
- Weiyu Ye
- , Anna Olsson-Brown
- & Benjamin P. Fairfax
-
Article |
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
- Jesper van Breeschoten
- , Michel W. J. M. Wouters
- & Alfonsus J. M. van den Eertwegh
-
Review Article
| Open AccessMitochondrial oxidative phosphorylation in cutaneous melanoma
- Prakrit R. Kumar
- , Jamie A. Moore
- & Marc D. Moncrieff
-
Article
| Open AccessUnderstanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study
- Aiden J. Smith
- , Paul C. Lambert
- & Mark J. Rutherford
-
Article
| Open AccessMelanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
- Prachi Bhave
- , Lalit Pallan
- & Andrew Haydon
-
Brief Communication
| Open AccessThe mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence
- Roy Rabbie
- , Peter Ferguson
- & David J. Adams
-
Brief Communication
| Open AccessNme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma
- Nidhi Pamidimukkala
- , Gemma S. Puts
- & David M. Kaetzel
-
Article
| Open AccessFirst-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
- Malaka Ameratunga
- , Irene Braña
- & Johann S de Bono
-
Review Article
| Open AccessIntratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
- Mark R. Middleton
- , Christoph Hoeller
- & Axel Hauschild
-
Article
| Open AccessImmune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
- Vincent Ting Fung Cheung
- , Tarun Gupta
- & Oliver Brain
-
Article
| Open AccessAlternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients
- Teresa Troiani
- , Emilio Francesco Giunta
- & Simona Romano
-
Comment
| Open AccessNew survival standards for advanced melanoma
- Lavinia Spain
- , James Larkin
- & Samra Turajlic
-
Article
| Open AccessDetection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
- Carlos Alberto Aya-Bonilla
- , Michael Morici
- & Elin Solomonovna Gray
-
Article
| Open AccessTargeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
- Manoela Tiago
- , Claudia Capparelli
- & Andrew E. Aplin
-
Article
| Open AccessDrug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies
- Ryan J. Ice
- , Michelle Chen
- & Sean D. McAllister
-
Article
| Open AccessDual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
- Avinash Gupta
- , Christopher Towers
- & Valentine Moya Macaulay
-
Article
| Open AccessIncreased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
- Teresa Delgado-Goñi
- , Teresa Casals Galobart
- & Mounia Beloueche-Babari
-
Comment
| Open AccessAre we over-treating with checkpoint inhibitors?
Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using evidence from melanoma research, both published and in process.
- Sarah Danson
- , Jane Hook
- & Pippa Corrie
-
Article
| Open AccessImpact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
- Karl D. Lewis
- , James Larkin
- & Axel Hauschild
-
Brief Communication
| Open AccessPatterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
- Jason Chesney
- , Igor Puzanov
- & Janice M. Mehnert
-
Correspondence |
Comment on “Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy”
- Vincenzo De Giorgi
- , Federica Scarfì
- & Piero Covarelli
-
Correspondence
| Open AccessReply to Comment on “Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy”
- Inês P. Santos
- , Peter J. Caspers
- & Gerwin J. Puppels
-
Article
| Open AccessReproductive factors, exogenous hormone use and incidence of melanoma among women in the United States
- Grayson M. Donley
- , Wayne T. Liu
- & Elizabeth K. Cahoon
-
Brief Communication
| Open AccessAntitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
- Omid Hamid
- , Caroline Robert
- & Marcus Butler
-
Editorial |
Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas
- Inês Pires da Silva
- , Marcel Batten
- & Georgina V. Long
-
Article
| Open Access25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
- Astrid Lipplaa
- , Ricardo Fernandes
- & Pippa G. Corrie
-
Article
| Open AccessS100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
- Nikolaus B Wagner
- , Andrea Forschner
- & Thomas K Eigentler
-
Article
| Open AccessTumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy
- Nikki R. Adler
- , Rory Wolfe
- & Victoria J. Mar
-
Clinical Study
| Open AccessHealth-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
- Brigitte Dréno
- , Paolo A Ascierto
- & Antoni Ribas
-
Molecular Diagnostics
| Open AccessDevelopment and validation of a plasma-based melanoma biomarker suitable for clinical use
- Ryan Van Laar
- , Mitchel Lincoln
- & Barton Van Laar
-
Translational Therapeutics
| Open AccessTargeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
- Chiao-En Wu
- , Arman Esfandiari
- & John Lunec
-
Molecular Diagnostics
| Open AccessFavourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients
- D Zugna
- , R Senetta
- & S Ribero
-
Molecular Diagnostics
| Open AccessPrognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma
- Emilia Hugdahl
- , May Britt Kalvenes
- & Lars A Akslen
-
Molecular Diagnostics
| Open AccessTumour mutation status and sites of metastasis in patients with cutaneous melanoma
- Nikki R Adler
- , Rory Wolfe
- & Victoria J Mar
-
Translational Therapeutics
| Open AccessModulating cancer cell survival by targeting intracellular cholesterol transport
- Omer F Kuzu
- , Raghavendra Gowda
- & Gavin P Robertson
-
Molecular Diagnostics
| Open AccessUV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins–TGF-β1–FAP-α
- Petra Wäster
- , Kyriakos Orfanidis
- & Karin Öllinger
-
Translational Therapeutics
| Open AccessEfficacy of anti-PD-1 therapy in patients with melanoma brain metastases
- Sagun Parakh
- , John J Park
- & Matteo S Carlino